Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camostat mesilate (Foipan) for mild to moderate COVID-19 at risk of ARDS
MOH_2020-04-07_008841Phase 2Recruiting
- Sponsor
- פרופ' איל משעני
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of camostat mesilate in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by פרופ' איל משעני. Primary endpoints: Lung injury reduction, Need for mechanical ventilation and 1 more. Started Apr 2020; status: recruiting.
02
Drugs
camostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2020-04-07_008841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-07_008841.